CCDC105 Inhibitors
CCDC105 inhibitors are a diverse group of chemical compounds that interact with various signaling pathways, potentially leading to the inhibition of the CCDC105 protein's functional activity. These inhibitors work through different mechanisms to achieve this effect, often involving the modulation of kinase activity or the alteration of specific signaling pathways that are essential for the functional regulation of CCDC105.
Staurosporine and chelerythrine, for instance, target kinase activity directly, which is crucial for the phosphorylation-dependent regulation of many proteins, including CCDC105. Inhibition of these kinases might prevent the phosphorylation that is necessary for CCDC105 activation or interaction with other cellular components. Similarly, Go6983 and other PKC inhibitors like chelerythrine can disrupt PKC-mediated pathways, potentially affecting CCDC105's activity by altering its phosphorylation state.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By inhibiting histone deacetylase, it leads to an increase in the acetylation of histones, which generally promotes transcription. However, in the context of CCDC105, if hyperacetylation leads to the upregulation of a repressor protein that specifically downregulates CCDC105, this would result in decreased CCDC105 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. The PI3K/AKT pathway is involved in numerous cellular processes including the regulation of transcription factors. Inhibition of PI3K could lead to a decrease in AKT phosphorylation, reducing the transcription of CCDC105 if it is AKT-dependent. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. If CCDC105 activity is dependent on ERK signaling, then inhibition of MEK would lead to decreased ERK activation and consequently reduce CCDC105 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. It inhibits p38 MAPK signaling which might be implicated in the regulation of CCDC105. If CCDC105 is activated by p38 MAPK-driven pathways, then inhibition by SB203580 would result in decreased CCDC105 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. It inhibits the mTOR pathway, which may play a role in the translation of specific proteins. If CCDC105 is translated in an mTOR-dependent manner, rapamycin can decrease its expression and thus its functional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the proteasome, it prevents the degradation of protein inhibitors that could be part of the ubiquitin-proteasome system regulating CCDC105 stability, leading to its decreased function. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine is a Hedgehog signaling pathway inhibitor. If CCDC105 function is regulated by components of the Hedgehog pathway, cyclopamine would decrease Hedgehog signaling, potentially reducing CCDC105 activity. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a gamma-secretase inhibitor. It inhibits the Notch signaling pathway. If CCDC105 activity is influenced by Notch signaling, inhibition by DAPT could lead to a reduction in CCDC105 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, another component of the MAPK/ERK pathway. Similar to U0126, by inhibiting MEK, PD98059 would decrease ERK activation, which could lead to a reduction in CCDC105 activity if it is ERK-dependent. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor like LY294002, and it would similarly lead to decreased AKT phosphorylation and potentially reduce CCDC105 function if it is regulated by the PI3K/AKT pathway. | ||||||